DE60332320D1 - Neues screening-verfahren - Google Patents

Neues screening-verfahren

Info

Publication number
DE60332320D1
DE60332320D1 DE60332320T DE60332320T DE60332320D1 DE 60332320 D1 DE60332320 D1 DE 60332320D1 DE 60332320 T DE60332320 T DE 60332320T DE 60332320 T DE60332320 T DE 60332320T DE 60332320 D1 DE60332320 D1 DE 60332320D1
Authority
DE
Germany
Prior art keywords
salt
screening procedure
new screening
eicosanoid
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60332320T
Other languages
English (en)
Inventor
Shuji Hinuma
Masaki Hosoya
Yasuaki Ito
Makoto Kobayashi
Hideyuki Tanaka
Shoichi Okubo
Ryo Fujii
Hideki Kizawa
Yuji Kawamata
Kazuhiro Ogi
Masataka Harada
Shoji Fukusumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE60332320D1 publication Critical patent/DE60332320D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60332320T 2002-02-14 2003-02-13 Neues screening-verfahren Expired - Lifetime DE60332320D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2002037131 2002-02-14
JP2002204163 2002-07-12
JP2002328696 2002-11-12
JP2003014032 2003-01-22
PCT/JP2003/001483 WO2003068959A1 (fr) 2002-02-14 2003-02-13 Nouveau procede de criblage

Publications (1)

Publication Number Publication Date
DE60332320D1 true DE60332320D1 (de) 2010-06-10

Family

ID=27739281

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60332320T Expired - Lifetime DE60332320D1 (de) 2002-02-14 2003-02-13 Neues screening-verfahren

Country Status (6)

Country Link
US (1) US7214495B2 (de)
EP (1) EP1479768B1 (de)
AT (1) ATE466030T1 (de)
AU (1) AU2003211952A1 (de)
DE (1) DE60332320D1 (de)
WO (1) WO2003068959A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056685B1 (en) 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
WO2004041266A1 (ja) * 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited 受容体機能調節剤
ATE511644T1 (de) * 2003-01-17 2011-06-15 Takeda Pharmaceutical Neues screening-verfahren
AU2004264314A1 (en) * 2003-08-18 2005-02-24 Betagenon Ab New diabetes type 2 animal model
WO2005086661A2 (en) 2004-02-27 2005-09-22 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
DE602004026360D1 (de) * 2004-03-01 2010-05-12 Pharmafrontier Co Ltd Pharmazeutische zusammensetzung zur herabsetzung des blutzuckerspiegels
JP4859665B2 (ja) * 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
US20060003344A1 (en) * 2004-06-30 2006-01-05 Pfizer Inc. Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
AU2006284926A1 (en) * 2005-09-02 2007-03-08 Arena Pharmaceuticals, Inc. Human G protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to MCP-1 expression
US20070122344A1 (en) * 2005-09-02 2007-05-31 University Of Rochester Medical Center Office Of Technology Transfer Intraoperative determination of nerve location
CA2621949A1 (en) * 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
JP4990789B2 (ja) 2005-11-04 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｇｐｒ４０とホスホリパーゼとを用いる疾患に有用な物質のスクリーニング方法
JP5075641B2 (ja) * 2006-01-31 2012-11-21 武田薬品工業株式会社 遺伝子改変動物およびその用途
EP2001844A2 (de) * 2006-03-14 2008-12-17 Amgen, Inc Bicyclische carbonsäurederivate zur behandlung von stoffwechselerkrankungen
CA2662305C (en) * 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
US20080161744A1 (en) 2006-09-07 2008-07-03 University Of Rochester Medical Center Pre-And Intra-Operative Localization of Penile Sentinel Nodes
CA2662242C (en) * 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
ES2446419T3 (es) * 2007-04-16 2014-03-07 Amgen, Inc Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos
US8318781B2 (en) 2007-04-26 2012-11-27 Japan Science And Technology Agency G-protein-conjugated receptor agonist
JP5591706B2 (ja) 2007-10-10 2014-09-17 アムジエン・インコーポレーテツド 置換ビフェニルｇｐｒ４０調節因子
US8406860B2 (en) 2008-01-25 2013-03-26 Novadaq Technologies Inc. Method for evaluating blush in myocardial tissue
CA2716352C (en) * 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
US10219742B2 (en) 2008-04-14 2019-03-05 Novadaq Technologies ULC Locating and analyzing perforator flaps for plastic and reconstructive surgery
WO2009135178A2 (en) 2008-05-02 2009-11-05 Flower Robert W Methods for production and use of substance-loaded erythrocytes (s-les) for observation and treatment of microvascular hemodynamics
US8748462B2 (en) * 2008-10-15 2014-06-10 Amgen Inc. Spirocyclic GPR40 modulators
US10492671B2 (en) 2009-05-08 2019-12-03 Novadaq Technologies ULC Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest
US10278585B2 (en) 2012-06-21 2019-05-07 Novadaq Technologies ULC Quantification and analysis of angiography and perfusion
CN107209118B (zh) 2014-09-29 2021-05-28 史赛克欧洲运营有限公司 在自体荧光存在下生物材料中目标荧光团的成像
CA2963450A1 (en) 2014-10-09 2016-04-14 Novadaq Technologies Inc. Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography
EP3580609B1 (de) 2017-02-10 2023-05-24 Stryker European Operations Limited Handhaltbare offenfeld-fluoreszenzbildgebungssysteme und verfahren

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
US7241579B2 (en) * 2000-12-22 2007-07-10 Smithkline Beecham Corporation Method of screening for GPR40 ligands
GB0031527D0 (en) * 2000-12-22 2001-02-07 Smithkline Beecham Plc New use

Also Published As

Publication number Publication date
EP1479768A1 (de) 2004-11-24
ATE466030T1 (de) 2010-05-15
EP1479768A4 (de) 2006-02-01
EP1479768B1 (de) 2010-04-28
US7214495B2 (en) 2007-05-08
US20050089866A1 (en) 2005-04-28
WO2003068959A1 (fr) 2003-08-21
AU2003211952A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
DE60332320D1 (de) Neues screening-verfahren
ATE490323T1 (de) Adiponektin-rezeptor und dafür kodierendes gen
WO2002084286A1 (fr) Procede de criblage
DE60322188D1 (de) Zytokin (zcytor17-ligand)
SE9704836D0 (sv) Novel receptor
DK1531682T3 (da) Fodersammensætning og fremgangsmåde til fodring af dyr
EP1741792A4 (de) Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon
ATE511644T1 (de) Neues screening-verfahren
DE602004030899D1 (de) Neues screening-verfahren
WO2005100386A3 (en) Canine cold-and menthol-sensitive receptor 1
WO2003021262A1 (fr) Procede de criblage
CY1109904T1 (el) Προαγωγεας της il-18bp, η παρασκευη και χρηση του
WO2003082320A1 (fr) Nouveau procede de criblage
DE602004023493D1 (de) Neues screening-verfahren
DE60329931D1 (de) Fprl1-liganden und deren verwendung
WO2003021263A1 (fr) Utilisation d'une proteine de recepteur couple a une proteine g
WO2003060516A1 (fr) Methode de criblage
SE9804274D0 (sv) Novel receptor
SE9902763D0 (sv) Novel receptor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition